WO2025195368 - CDK INHIBITOR COMPOUNDS
National phase entry is expected:
Publication Number
WO/2025/195368
Publication Date
25.09.2025
International Application No.
PCT/CN2025/083184
International Filing Date
18.03.2025
Title **
[English]
CDK INHIBITOR COMPOUNDS
[French]
COMPOSÉS INHIBITEURS DE CDK
[Chinese]
CDK抑制剂化合物
Applicants **
SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO., LTD.
Inventors
JIN, Jinghai
ZHU, Wei
BAI, Gang
YANG, Shuqun
ZHOU, Lei
LI, Zhengtao
Priority Data
202410319396.X
19.03.2024
CN
202411079678.3
07.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2163 | |
| EPO | Filing, Examination, Granting | 17375 | |
| Japan | Filing, Examination, Granting | 2524 | |
| South Korea | Filing, Examination, Granting | 2802 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
30,804
Contact Us
Abstract[English]
The present disclosure relates to CDK4 inhibitor compounds represented by formula (I) or pharmaceutically acceptable salts thereof, a pharmaceutical composition containing same, and the use thereof in preventing or treating CDK4-mediated diseases.[French]
La présente invention concerne des composés inhibiteurs de CDK4 représentés par la formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, une composition pharmaceutique les contenant, et leur utilisation dans la prévention ou le traitement de maladies médiées par CDK4.[Chinese]
本公开涉及式(I)所示CDK4抑制剂化合物或其药学上可接受的盐、含有它们的药物组合物、以及其在制备预防或治疗CDK4介导的疾病中的用途。